Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved Encelto ...

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study ...

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and ...

Neurotech Pharmaceuticals, Inc. (the “Company”) announces the launch of YouTube channel - Uncovering MacTel, a new disease education resource that delivers accessible, patient-centered information for ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel in macular telangiectasia type 2 (MacTel), as well as the importance of ...

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia (MacTel) type 2, Neurotech Pharmaceuticals announced on Thursday. A rare, ...

CUMBERLAND, R.I., June 02, 2026--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc. (the "Company") announces the launch of YouTube channel - Uncovering MacTel, a new disease education resource that ...